<code id='18C7A76217'></code><style id='18C7A76217'></style>
    • <acronym id='18C7A76217'></acronym>
      <center id='18C7A76217'><center id='18C7A76217'><tfoot id='18C7A76217'></tfoot></center><abbr id='18C7A76217'><dir id='18C7A76217'><tfoot id='18C7A76217'></tfoot><noframes id='18C7A76217'>

    • <optgroup id='18C7A76217'><strike id='18C7A76217'><sup id='18C7A76217'></sup></strike><code id='18C7A76217'></code></optgroup>
        1. <b id='18C7A76217'><label id='18C7A76217'><select id='18C7A76217'><dt id='18C7A76217'><span id='18C7A76217'></span></dt></select></label></b><u id='18C7A76217'></u>
          <i id='18C7A76217'><strike id='18C7A76217'><tt id='18C7A76217'><pre id='18C7A76217'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:leisure time    - browse:76379
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment